Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MIDATECH PHARMA PLC. We currently have 56 research reports from 4 professional analysts.
|20Jan17 11:05||RNS||Second Price Monitoring Extn|
|20Jan17 11:00||RNS||Price Monitoring Extension|
|20Jan17 07:00||RNS||Trading Update|
|20Dec16 12:56||RNS||Director/PDMR Shareholding|
|15Dec16 04:31||RNS||Holding(s) in Company|
|22Nov16 07:00||RNS||Midatech receives upfront on Emergex vaccine deal|
|15Nov16 07:00||RNS||Midatech selects MTR104 for liver cancer treatment|
Frequency of research reports
Research reports on
MIDATECH PHARMA PLC
MIDATECH PHARMA PLC
N+1 Singer - Midatech Pharma - FY trading update: revenue ahead of estimates
20 Jan 17
Midatech’s FY trading update indicates revenue for the period of c. £9.0m, ahead of our £8.0m estimate. The £16.7m (gross) capital raise announced in October allows Midatech to accelerate development of its key programmes. We continue to expect data from a gold nanoparticle (GNP) enabled Phase I diabetes vaccine trial in 2017, followed by the start of clinical trials in brain and liver cancer by early 2018. In addition, Q-Octreotide in our view represents a significant near-term licensing opportunity. We reiterate our Buy recommendation.
Panmure Morning Note 20-01-2017
20 Jan 17
Midatech Pharma’s trading update for the 12 months to 31 December 2016 reports ‘good progress across the group’ with total reported revenues expected to be circa £9.0m (2015: £1.4m). On this basis, the revenue performance for the year comes in-line with our top-of-the-range forecast (and is circa +4.9% vs consensus) and provides excellent validation of the group’s commercial capabilities and the potential of its US commercial presence. We believe the news flow, particularly as we look towards updates on Q-Octreotide in the coming months, reflects management’s ambitions and capabilities in building an international specialty pharmaceutical business, and we consider the wider business well-set to continue on its planned growth profile. Buy.
Panmure Morning Note 22-11-2016
22 Nov 16
Midatech’s previously-announced programme (04 January 2016) in conjunction with Emergex (infectious disease) has today crystallised an upfront technology access fee and option payment of £450,000 to Midatech. We think today’s news represents a strong validating point within the relationship between the two companies and consider the programme sits in a highly complementary manner alongside Midatech’s programmes in immunotherapy, auto-immune disease and immuno-oncology. We remain Buyers and repeat our 297p target price.
Panmure Morning Note 15-11-2016
15 Nov 16
While Midatech’s liver cancer programme has been perhaps overshadowed by the strength of news flow generated by other areas within its development portfolio (e.g. recent progress with Q-Octreotide MTD201, OpsiSporin and MTX110/MTX111 for the treatment of DIPG), this morning’s announcement of the selection of a wholly-owned candidate compound MTR104 sees the liver programme continue on track with previously announced timelines. This should see MTR104 taken into a formal IND-enabling programme during 2017, followed by human studies planned for 2018. An area of significant unmet clinical need, we consider this another key programme with Midatech’s development stable. We repeat our Buy recommendation.
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
19 Jan 17
Aggregated Micro Power* (AMPH): Funding for first peaking power plant project (CORP) | The Mission Marketing Group* (TMMG): Positive trading update (CORP) | Cello (CLL): Increasingly backed by, and leveraging, technology (BUY) | 4imprint (FOUR): Growth backed by strong cash flow continues (BUY) | Allergy Therapeutics (AGY): Positive trading update and market share gains drive upgrades (BUY) | Shanta Gold (SHG): Q4 operating results (BUY) | Sound Energy (SOU): Tendrara extended well test result (BUY) | Revolution Bars (RBG): Price target increase (BUY)
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
APPLIED GRAPHENE MATERIALS PLC (AGM LN) | BELLWAY (BWY LN) | GOALS SOCCER CENTRES (GOAL LN) | GRAFENIA PLC (GRA LN) | GRAINGER PLC (GRI LN) | GREGGS (GRG LN) | HARGREAVES SERVICES (HSP LN) | IMMUNODIAGNOSTIC SYSTEMS HLDGS (IDH LN) | INSTEM PLC (INS LN) | KROMEK GROUP PLC (KMK LN) | NORTHGATE PLC (NTG LN) | QUANTUM PHARMA PLC (QP/ LN) | RHYTHMONE PLC (RTHM LN) | SCS GROUP PLC (SCS LN) | SHIELD THERAPEUTICS PLC (STX LN) | SQS SOFTWARE QUALITY SYSTEMS AG (SQS LN) | UTILITYWISE PLC (UTW LN) | VERTU MOTORS PLC (VTU LN) | VISLINK PLC (VLK LN) | ZYTRONIC (ZYT LN)
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
ACTUAL EXPERIENCE PLC (ACT LN) | BAGIR GRP LTD (BAGR LN) | BIOQUELL (BQE LN) | BROWN(N.)GROUP (BWNG LN) | CARADOR INCOME FUND PLC (CIFU LN) | HALFORDS GROUP (HFD LN) | NCC GROUP (NCC LN) | ST IVES PLC (SIV LN) | SUMMIT THERAPEUTICS PLC (SUMM LN) | WILMINGTON PLC (WIL LN)
Demanding targets exceeded
17 Jan 17
Sinclair is a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics products, which target unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments, which is a significant growth opportunity. Sinclair has an established sales and marketing presence in Europe, direct sales in Brazil, and operates through an international group of distributors in other markets, including SE Asia and the US. With the benefit of a strong balance sheet, Sinclair is investing in an accelerated growth phase and margin expansion.